The Clinical Study on the IV Stage of Type 2 Diabetic Nephropathy Treated with Sodium Ferulate and Olmesartan

Objective:To investigate the protective effects of combination of sodium ferulate and olmesartan on the Ⅳ Stage of type 2 diabetic nephropathy.Methods:One hundred and sixty patients with type 2 diabetic nephropathy in phase Ⅳwere enrolled and randomly divided into the control group(controlling the blood glucose,reducing blood lipids,meanwhile reducing the blood pressure and proteinuria with olmesartan 40 mg/d) and the treatment group(add Sodium Ferulate 300 mg·d-1 for 30 days).The treatment lasted for 30 days,and the levels of all parameters asserum ET-1,serum creatinine、BUN,serum TG、TC,24 hours quantity for urinary albumin,urinary RBP,β2-MG were measured before and after the therapy.Results:The serum Creatinine、BUN、ET-1、TGF-β1,24 h UALB;urinaryβ2-MG、urinaryRBP in both groups were improved.and there was statistical difference between these two groups(P0.05).The levels of all parameters of renal tubular function,as urinary RBP,β2-MG,declined in the treatment group.Compared with the control group,there were significant statistical differences(P0.05).Conclusion:The sodium ferulate on phase Ⅳ Of type 2 diabetic nephropathy has significant protective effects for reducing proteinuria,delaying the process of renal failure and fibrosis;however,more evidences will be needed.